The number of gene expression studies related to the pathology and treatment of COVID-19 has strongly increased in the past months. Researchers characterize this disease at the molecular level using a variety of approaches and perspectives.
The following table describes high-quality human and mouse RNA-Seq and microarray studies that have been curated and integrated into GENEVESTIGATOR® for research on COVID-19. Included in this collection are primarily studies investigating molecular changes associated with SARS-CoV-2 infections, as well as secondary studies investigating experimental COVID-19 treatments (repurposed) in the context of their original use.
Stay tuned to explore more curated high-quality gene expression studies!
|GENEVESTIGATOR ID||Repository ID (s)||Study Title||Number of Samples|
|HS-03427||GSE47963 (superseries of GSE47960, GSE47961, GSE47962)||SARS-CoV, SARS-dORF6 and SARS-BatSRBD infection of HAE cultures.||438|
|HS-03426||GSE45042||Cell host-response to infection with novel human coronavirus EMC predict potential antivirals and important differences with SARS-coronavirus||32|
|HS-03424||GSE56677||Cytokine stimulation systems approach demonstrates differences in innate and pro-inflammatory host responses between genetically distinct MERS-CoV isolates.||32|
|HS-03423||GSE37827||SCL006, icSARS CoV Urbani or icSARS Bat SRBD (spike receptor binding domain from the wild type strain Urbani to allow for infection of human and non-human primate cells) infections of the 2B4 clonal derivative of Calu-3 cells - Time course||87|
|HS-03422||GSE33267||SCL005: icSARS CoV Urbani or icSARS deltaORF6 infections of the 2B4 clonal derivative of Calu-3 cells - Time course||99|
|HS-03420||GSE147507||Transcriptional response to SARS-CoV-2 infection||67|
|HS-03375||GSE148817 (part of GSE148818)||Cell-intrinsic differences between human tracheal epithelial cells from children and adults||6|
|HS-03244||GSE78068||Identification of baseline gene expression signatures predicting therapeutic responses to three biologic agents in rheumatoid arthritis: a retrospective observational study||209|
|HS-02837||GSE25160||Combination of peripheral blood gene expression profiles and clinical parameters predicts response for tocilizumab (anti-IL6) treatment in rheumatoid arthritis||26|
|HS-02781||GSE46293 (Superserie of GSE46280, GSE46282, GSE46283, GSE46292)||Expression data of multiple sclerosis patients receiving Interferon-beta therapy||24|
|HS-01798||GSE56192 (part of GSE56189)||Transcriptomic analysis of the Novel Middle East Respiratory Syndrome Coronavirus (Human, MRC5 cells)||25|
|HS-01477||GSE17183||Hepatic gene expression before and during interferon and ribavirin combination therapy||98|
|HS-01237||GSE45867||Effects of tocilizumab versus methotrexate therapy on gene expression profiles in the early rheumatoid arthrtis synovium||40|
|HS-00214||GSE7123||Gene profiling of responders and non-responders to antiviral therapies peg interferon and ribavirin against hepatitis C||341|
|MM-01639||GSE148829||SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues||65|
|MM-01637||GSE59185, GSE52920||Host responses contributing to the attenuation of severe acute respiratory syndrome coronaviruses missing E protein domains / GSE52920||18|
|MM-01636||GSE131936||Relative timing of type I interferon response and virus replication determines disease outcome during MERS-CoV infection||16|
|MM-01635||GSE146074||LY6E blocks coronavirus fusion and confers immune control of viral disease||36|
|MM-01632||GSE49262, GSE49263||SM012 - SARS MA15 wild type, and SARS deltaORF6 mutant virus infections of C57BL6 mice - A time course||75|
|MM-00498||GSE21583||Effects of ACE2 on BMPR2 mutation-mediated defects in gene expression||8|
|MM-01448||GSE84709||Expression data of Brain CD11b+ cells from WT and DP1 knockout mice infected with rJ2.2||7|
|MM-01140||GSE36016||Transcriptomic analysis of host response to mouse-adapted SARS virus in wild type, STAT1 -/-, and IFNAR1 -/- mouse genetic backgrounds||36|
|MM-01109||GSE51386||SM004 - SARS infection of C57BL6, TIMP1 and Serpine1 knock-out mice||38|
Table: These human and mouse RNA-Seq and Microarray studies in GENEVESTIGATOR® investigate gene expression changes associated with SARS-CoV-2 and changes associated with experimental treatments of COVID-19.